Infection Risk Does Not Seem to Differ Among Biologics for Psoriasis
Differential risk for serious infection or respiratory tract infection, including SARS-CoV-2, not seen among biologics used to treat psoriasis
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.